

Paper No. \_\_\_\_\_  
Filed: April 5, 2018

Filed on behalf of: Mylan Pharmaceuticals Inc.

By: Robert L. Florence (robertflorence@parkerpoe.com)  
Karen L. Carroll (karencarroll@parkerpoe.com)  
Micheal L. Binns (michealbinns@parkerpoe.com)  
Sharad K. Bijanki (sharadbijanki@parkerpoe.com)  
Parker Poe Adams & Bernstein LLP

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

MYLAN PHARMACEUTICALS INC.

Petitioner,

v.

BRISTOL-MYERS SQUIBB COMPANY and PFIZER INC. ,  
Patent Owners.

---

IPR2018-00892

U.S. Patent No. 9,326,945 to Patel *et al.*

Issue Date: May 3, 2016

Title: Apixaban Formulations

**PETITION FOR *INTER PARTES* REVIEW OF  
U.S. PATENT NO. 9,326,945**

## TABLE OF CONTENTS

<b>I.</b>	<b>INTRODUCTION .....</b>	<b>1</b>
<b>II.</b>	<b>MANDATORY NOTICES .....</b>	<b>1</b>
	A. REAL PARTIES-IN-INTEREST UNDER 37 C.F.R. § 42.8(B)(1) .....	1
	B. RELATED MATTERS UNDER 37 C.F.R. § 42.8(B)(2) .....	1
	C. LEAD AND BACK-UP COUNSEL UNDER 37 C.F.R. § 42.8(B)(3) .....	3
	D. SERVICE INFORMATION UNDER 37 C.F.R. § 42.8(B)(4) .....	4
<b>III.</b>	<b>GROUND FOR STANDING UNDER 37 C.F.R. § 42.104(A) .....</b>	<b>4</b>
<b>IV.</b>	<b>IDENTIFICATION OF CHALLENGE AND STATEMENT OF THE PRECISE RELIEF REQUESTED (37 C.F.R. § 42.22(A) AND 37 C.F.R. § 42.104(B)) .....</b>	<b>4</b>
<b>V.</b>	<b>THRESHOLD REQUIREMENT FOR INTER PARTES REVIEW .....</b>	<b>5</b>
<b>VI.</b>	<b>STATEMENT OF REASONS FOR THE RELIEF REQUESTED .....</b>	<b>5</b>
	A. SUMMARY OF THE ARGUMENT .....	5
	B. LEVEL OF ORDINARY SKILL IN THE ART .....	8
	C. THE '945 PATENT AND ITS PROSECUTION HISTORY .....	8
	1. The '945 Patent .....	8
	2. The Disclosure of the '945 Patent .....	11
	3. The Prosecution History of the '945 Patent .....	13
	a. Office Action (February 28, 2014) .....	13
	b. August 13, 2015 Office Action .....	14
	c. Interview/Response .....	15
	d. Notice of Allowance/Notice of Allowability .....	16
	D. CLAIM CONSTRUCTION UNDER 37 C.F.R. § 42.104(B)(3) .....	16
	E. THE PRIOR ART CITED IN THIS PETITION IS NOT REDUNDANT TO PRIOR ART CONSIDERED DURING PROSECUTION .....	17
	F. SCOPE AND CONTENT OF THE PRIOR ART .....	17
	1. The Use of Anti-Coagulant Agents to Treat Thromboembolic Disease .....	17
	2. Apixaban Was a Well-Known Anticoagulant .....	18
	a. The '208 Patent .....	19
	3. Apixaban Was Known to Have Poor Solubility .....	20
	a. Carreiro .....	23
	b. Pinto .....	24
	c. Nause .....	25

	d.	Wei.....	26
4.		Routine Techniques for Optimizing the Solubility of a Compound Were Well-Known and Included Reducing Particle Size and Adding a Surfactant .....	27
	a.	Ashford.....	27
	b.	Rudnic .....	28
	c.	Stegemann .....	29
	d.	The '506 Patent .....	30
	e.	FDA Dissolution Guidance .....	31
G.		GROUND 1: CARREIRO IN VIEW OF WEI AND THE FDA DISSOLUTION GUIDANCE RENDER CLAIMS 1-38 OF THE '945 PATENT OBVIOUS UNDER 35 U.S.C. § 103(A) .....	33
	1.	Motivation to Combine.....	34
	2.	Reasonable Expectation of Success.....	37
	3.	Carreiro combined with Wei and the FDA Dissolution Guidance Rendered Claim 1 Obvious .....	39
	a.	Limitation 1(a): “A solid pharmaceutical composition comprising a therapeutically effective amount of crystalline apixaban particles.” .....	39
	b.	Limitation 1(b): “a pharmaceutically acceptable diluent or carrier” .....	41
	c.	Limitation 1(c): “wherein the crystalline apixaban particles have a D <sub>90</sub> equal to or less than about 89 μm,” .....	42
	d.	Limitation 1(d): “and wherein at least 77 wt% of apixaban dissolves within 30 minutes in a pH 6.8 phosphate buffer containing 0.05% sodium lauryl sulfate.” .....	42
	4.	Independent Claim 12: “A solid pharmaceutical composition comprising ... [d] wherein, as measured using a USP Apparatus 2 at a paddle rotation speed of 75 rpm in 900 mL, of a dissolution medium at 37° C., at least 77 wt % of apixaban in the pharmaceutical composition dissolves within 30 minutes in the dissolution medium, and the dissolution medium is 0.05 M sodium phosphate at a pH 6.8 containing 0.05% sodium lauryl sulfate.” .....	44
	5.	Claims 2 and 13: “The composition as defined in claim[s] 1 or 12], wherein said composition comprises Form N-1 of apixaban.” .....	45

6.	Claims 3 and 14: “The composition as defined in claim[s 1 or 12], wherein the D <sub>90</sub> is equal to or less than 85 μm.” .....	45
7.	Claims 4 and 15: “The composition as defined in claim[1 or 12], wherein the D <sub>90</sub> is equal to or less than 50 μm.” .....	45
8.	Claims 5 and 16: “The composition as defined in claim[s 1 or 12], wherein the D <sub>90</sub> is equal to or less than 30 μm.” .....	45
9.	Claims 6 and 17: “The composition as defined in claim[s 1 or 12], wherein the D <sub>90</sub> is equal to or less than 25 μm.” .....	46
10.	Claims 7 and 18: “The composition as defined in claim[s 1 or 12], further comprising: from 1% to 2% by weight of a surfactant.” .....	46
11.	Claims 8 and 19: “The composition as defined in claim[s 7 and 18], wherein the surfactant is sodium lauryl sulfate.” .....	47
12.	Claims 9-11 and 20-22: “The composition as defined in claim[s 1 or 12], wherein the pharmaceutical composition comprises [between 2.5 and 5 mg] of apixaban.” .....	48
13.	Claims 23, 25, 27, 29, 31, 33, 35 and 37: “The composition as defined in claim[s 1, 9-12, and 20-22], which is a tablet.” ..	48
14.	Claims 24, 26, 28, 30, 32, 34, 36 and 38: “The composition as defined in claim[s 1, 9-12, 20-22], which is a capsule.” .....	49
H.	GROUND 2: CARREIRO AND WEI, IN VIEW OF RUDNIC AND FDA DISSOLUTION GUIDANCE RENDER CLAIMS 1-38 OF THE '945 PATENT OBVIOUS UNDER 35 U.S.C. § 103(A.) .....	49
1.	Motivation to Combine References and Reasonable Expectation of Success .....	49
a.	Claims 1, 3-6, 12 and 13-17 .....	50
b.	Claims 7-8 and 18-19 .....	50
c.	Claims 9-11, 20-38 .....	51
I.	GROUND 3: THE '208 PATENT AND WEI, IN VIEW OF THE FDA DISSOLUTION GUIDANCE RENDER CLAIMS 1-38 OF THE '945 PATENT OBVIOUS UNDER 35 U.S.C. § 103(A.) .....	51
1.	Motivation to Combine References and Reasonable Expectation of Success .....	52
2.	Claim 1 .....	53
a.	Limitations 1(a)-(b) .....	53
b.	Limitation 1(c) .....	54
c.	Limitation 1(d) .....	55
3.	Claim 12 .....	56

4.	Claims 2 and 13 .....	56
5.	Claims 3-6 and 14-17 .....	57
6.	Claims 7-8 and 18-19 .....	57
7.	Claims 9-11 and 20-22 .....	58
8.	Claims 23-38 .....	58
J.	GROUND 4: THE '208 PATENT AND WEI, IN VIEW OF RUDNIC AND THE FDA DISSOLUTION GUIDANCE RENDER CLAIMS 1-38 OF THE '945 PATENT OBVIOUS UNDER 35 U.S.C. § 103(A.) .....	59
1.	Motivation to Combine References and Reasonable Expectation of Success .....	59
a.	Claims 1, 3-6, 12, and 13-17 .....	59
b.	Claims 7-8 and 18-19 .....	60
c.	Claims 9-11 and 20-38 .....	61
K.	NO SECONDARY CONSIDERATIONS SUPPORT NONOBVIOUSNESS.....	61
1.	There Are No Unexpected Results .....	62
2.	The '945 Patent Did Not Satisfy Any Long-Felt But Unmet Need .....	64
3.	There Was No Industry Skepticism.....	65
4.	There is No Evidence of Commercial Success.....	65
5.	Copying by Generic Drug Makers is Irrelevant.....	67
<b>VII.</b>	<b>CONCLUSION .....</b>	<b>67</b>

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.